TrialBritish journal of haematology2018

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.

Wojciech Jurczak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.